Edition:
United States

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

1.56USD
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
$1.56
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
270,287
52-wk High
$2.87
52-wk Low
$1.32

Chart for

About

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting... (more)

Overall

Beta: 2.22
Market Cap(Mil.): $369.43
Shares Outstanding(Mil.): 217.31
Dividend: --
Yield (%): --

Financials

  IDRA.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -0.42 -- --
ROI: -74.79 -5.87 13.17
ROE: -75.13 -7.71 15.15

BRIEF-Idera Pharmaceuticals Reports Q1 Loss Per Share $0.10

* IDERA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 09 2018

BRIEF-Idera Pharmaceuticals Enters Into A Clinical Development Support Agreement With Pillar Partners Foundation

* IDERA PHARMACEUTICALS ENTERS INTO A CLINICAL DEVELOPMENT SUPPORT AGREEMENT WITH PILLAR PARTNERS FOUNDATION TO EXPAND THE CLINICAL RESEARCH ON IMO-2125 BEYOND PD-1 REFRACTORY MELANOMA

Apr 16 2018

BRIEF-Biocryst Pharmaceuticals And Idera Pharmaceuticals Reschedule Meetings To Vote On Proposed Merger

April 10 Idera Pharmaceuticals Inc - New Clinical Data On Idera's Imo :

Apr 10 2018

BRIEF-Idera Pharma Files Definitive Proxy Statement Over With Pending Merger With Biocryst

* IDERA PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH BIOCRYST PHARMACEUTICALS

Apr 02 2018

BRIEF-RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger With Idera Pharmaceuticals

* RA CAPITAL MANAGEMENT OPPOSES BIOCRYST PHARMACEUTICALS' PROPOSED MERGER WITH IDERA PHARMACEUTICALS

Apr 02 2018

BRIEF-Biocryst Pharmaceuticals Files Definitive Proxy Statement Related To Pending Merger With Idera Pharmaceuticals

* BIOCRYST PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH IDERA PHARMACEUTICALS

Apr 02 2018

BRIEF-Idera Pharmaceuticals Reports Q4 Loss Per Share $0.08

* IDERA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 07 2018

BRIEF-Idera Pharma Announces Launch Of Phase 3 Trial Evaluating IMO-2125 In Combination With Ipilimumab

* IDERA PHARMACEUTICALS ANNOUNCES LAUNCH OF GLOBAL PHASE 3 TRIAL EVALUATING IMO-2125 IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ANTI-PD-1 REFRACTORY MELANOMA (ILLUMINATE 301) Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 01 2018

BRIEF-Great Point Partners Opposes Biocryst Pharma Proposed Merger With Idera Pharma

* GREAT POINT PARTNERS LLC OPPOSES THE BIOCRYST PHARMACEUTICAL PROPOSED MERGER WITH IDERA PHARMACEUTICALS, INC.

Feb 16 2018

BRIEF-Biocryst Pharma And Idera Pharma Sign Merger Agreement To Form New Company

* BIOCRYST PHARMACEUTICALS AND IDERA PHARMACEUTICALS ANNOUNCE MERGER TO COMBINE CAPABILITIES TO SERVE MORE PATIENTS WITH RARE DISEASES

Jan 22 2018

Earnings vs. Estimates